#United States #San Diego #Class Action #Robbins LLP #Rocket Pharmaceuticals

Robbins LLP Class Action Alert for Rocket Pharmaceuticals, Inc.

On June 12, 2025, Robbins LLP, a prominent law firm specializing in shareholder rights, officially informed investors about a class action filed on behalf of stockholders of Rocket Pharmaceuticals, Inc. (NYSE: RCKT). This class action targets those who purchased or acquired Rocket securities between February 7, 2025, and May 26, 2025. This alarming legal development emerged amidst Rocket’s ongoing venture in gene therapies aimed at combating rare diseases, notably through their RP-A501 drug, which is currently in a pivotal Phase 2 trial.

Background on Rocket Pharmaceuticals

Rocket Pharmaceuticals is recognized as a biotechnology innovator, focusing on developing gene therapies designed to rectify genetic issues at their root cause. The company aims to offer hope for patients suffering from devastating conditions with their efficient and clear clinical development pathways. However, this recent class action highlights deeply concerning allegations regarding the company’s communication with its investors.

Allegations of Misleading Information

The core allegations against Rocket Pharmaceuticals stem from claims that the company knowingly provided misleading information about its RP-A501 drug and the associated clinical trials. According to the class action complaint, the defendants purportedly created a deceptive image of reliability concerning the treatment timeline and the safety evaluations tied to the RP-A501 drug.

A grave incident involving one of the trial participants, who tragically experienced a Serious Adverse Event (SAE) leading to their death, has exacerbated these allegations. Following this event, it was revealed that Rocket had made undisclosed amendments to the trial protocol that introduced a novel treatment agent, raising significant safety concerns. These events culminated in the FDA placing a hold on further enrollment for the trial, highlighting the seriousness of the purported omissions by the company.

On May 27, 2025, Rocket released a press statement acknowledging that a trial participant suffered an unexpected SAE, which caused a massive decline in the company’s stock price, plummeting from $6.27 per share to a low of $2.33 in a matter of days. This sudden decrease sparked outrage among investors, leading to the current class action.

Next Steps for Investors

Investors affected by the events involving Rocket Pharmaceuticals may have the opportunity to participate in this class action lawsuit. Shareholders interested in serving as lead plaintiffs, which would involve directing the litigation and representing the interests of the entire class, are encouraged to reach out to Robbins LLP. It is important to note that one does not need to actively participate in the case to be eligible for a financial recovery. Those who prefer to remain less involved can simply remain absent class members.

Robbins LLP operates on a contingency fee basis, ensuring that shareholders incur no upfront costs or expenses. This model emphasizes the firm’s commitment to representing shareholders and holding corporate executives accountable for potential wrongdoings.

About Robbins LLP

Established in 2002, Robbins LLP has garnered a reputation as a leader in shareholder rights litigation. The firm has focused on aiding shareholders in recovering losses and promoting sound corporate governance practices. As they navigate complex legal matters, Robbins continues its dedication to enhancing the landscape of shareholder protection.

For shareholders seeking updates regarding the class action or wanting to learn more about their rights, signing up for Stock Watch could provide essential notifications on settlements or alerts pertaining to corporate misbehavior.

In conclusion, the situation with Rocket Pharmaceuticals serves as a critical reminder of the inherent risks in investing, particularly in groundbreaking biotechnologies. As the class action unfolds, the focus will remain not only on achieving justice for the affected shareholders but also on ensuring a transparent and accountable corporate environment moving forward.

• ---

Contact Information

For inquiries or further information, shareholders can reach out directly to Robbins LLP at (800) 350-6003 or fill out a contact form available on their website.